MSeaman_Job_1_of_1

Printed by HPS Server

for

EAST

Please Scan

Printer: rem_05c70_gbuhptr

Date: 03/02/04

Time: 15:15:06

Document Listing

Document	Selected Pages	Page Range	Copies
US005585378	16	1 - 16	1
US005340366	6	1 - 6	1
US005279616	7	1 - 7	1
US005261926	7	1 - 7	1
US005190564	7	1 - 7	1
US004921503	6	1 - 6	1
Total (6)	49	-	-

WO 94/29272
WO 93/12085

more clear for recording than US Pats ...

* * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:37:16 ON 25 FEB 2004

=> file reg

=>
Uploading 09284516.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 [@1-@2],[@3-@4]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
L3 11 SEA SSS FUL L1

=> file ca

=> s l3
L4 1 L3

=> d ibib abs hitstr

L4 ANSWER 1 OF 1 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 131:209113 CA
TITLE: Antimycobacterial isatin and oxindole derivatives for the treatment of mycobacterial diseases
INVENTOR(S): Ramachandran, Janakiraman
PATENT ASSIGNEE(S): Astra AB, Swed.

SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9944608	A1	19990910	WO 1999-SE319	19990304
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2320757	AA	19990910	CA 1999-2320757	19990304
AU 9927573	A1	19990920	AU 1999-27573	19990304
AU 735381	B2	20010705		
BR 9908510	A	20001121	BR 1999-8510	19990304
EP 1058548	A1	20001213	EP 1999-908059	19990304
EP 1058548	B1	20030917		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002505286	T2	20020219	JP 2000-534210	19990304
NZ 506217	A	20020531	NZ 1999-506217	19990304
AT 249828	E	20031015	AT 1999-908059	19990304
NO 2000004419	A	20001020	NO 2000-4419	20000905

PRIORITY APPLN. INFO.: IN 1998-MA464 A 19980306
SE 1998-1370 A 19980420
WO 1999-SE319 W 19990304

OTHER SOURCE(S): MARPAT 131:209113

AB The use of certain isatin and oxindole derivs. in the prepn. of a medicament for use in the treatment of mycobacterial diseases is disclosed. Thus, 1-nonyl-7-phenyl-1H-indol-2,3-dione was prepd. by the reaction of 1-bromononane with 7-phenyl-1H-indole-2,3-dione (I). The MIC of I against Mycobacterium tuberculosis was .ltoreq.20 .mu.g/mL.

IT **242792-94-5P 242792-96-7P 242792-97-8P**
242792-98-9P 242792-99-0P 242793-00-6P
242793-01-7P 242793-02-8P 242793-03-9P
242793-04-0P 242793-05-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antimycobacterial isatin and oxindole derivs. for treatment of mycobacterial diseases)

RN 242792-94-5 CA
CN 1H-Indole-2,3-dione, 1-nonyl-7-phenyl- (9CI) (CA INDEX NAME)



RN 242792-96-7 CA
CN 1H-Indole-2,3-dione, 1-heptyl-7-phenyl- (9CI) (CA INDEX NAME)



RN 242792-97-8 CA
CN 1H-Indole-2,3-dione, 1-octyl-7-phenyl- (9CI) (CA INDEX NAME)



RN 242792-98-9 CA
CN 1H-Indole-2,3-dione, 1-decyl-7-phenyl- (9CI) (CA INDEX NAME)



RN 242792-99-0 CA
CN 1H-Indole-2,3-dione, 7-phenyl-1-undecyl- (9CI) (CA INDEX NAME)



RN 242793-00-6 CA
CN 1H-Indole-2,3-dione, 1-pentyl-7-phenyl- (9CI) (CA INDEX NAME)



RN 242793-01-7 CA
CN 1H-Indole-2,3-dione, 1-butyl-7-phenyl- (9CI) (CA INDEX NAME)



RN 242793-02-8 CA
CN 1H-Indole-2,3-dione, 1-(2-methylpropyl)-7-phenyl- (9CI) (CA INDEX NAME)



RN 242793-03-9 CA
CN 1H-Indole-2,3-dione, 1-hexyl-7-phenyl- (9CI) (CA INDEX NAME)



RN 242793-04-0 CA
CN 1H-Indole-2,3-dione, 1-dodecyl-7-phenyl- (9CI) (CA INDEX NAME)



RN 242793-05-1 CA
CN 1H-Indole-2,3-dione, 1-(4-bromobutyl)-7-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file marpat

=> s l1 full
L5 35 SEA SSS FUL L1

=> d ibib abs fqhit 1-35

L5 ANSWER 1 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 139:101024 MARPAT
TITLE: Preparation of 2-oxindole derivs. as glycogen synthase kinase-3 (GSK3) inhibitors for use in pharmaceutical compositions for treatment of neurodegenerative diseases
INVENTOR(S): Berg, Stefan; Bhat, Ratan; Edwards, Philip; Hellberg, Sven
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055492	A1	20030710	WO 2002-SE2370	20021218

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-344887P 20011221
GI



I



II

AB 2-Oxindoles, such as I [R = substituted- or unsubstituted-quinazolin-4-yl; R2 = OH, CH2F, CF3, OCF3, CN, NH2, NO2, alkyl, alkoxy, acyloxy, acyl, alkylthio, etc.; m = 0-4], were prepd. for therapeutic use as GSK3 inhibitors. These oxindoles are intended for therapeutic use in the treatment of GSK3 assocd. diseases, such as Alzheimer's disease, dementia, Parkinson dementia complex of Guam, frontotemporal dementia Parkinson's type, HIV dementia, neurofibrillar tangle pathologies, predemented states, vascular dementia, dementia with Lewy bodies, dementia pugilistic and age related cognitive disorders, as well as for male contraception and treatment of diabetes, amyotrophic lateral sclerosis, corticobasal degeneration, Down's syndrome, Huntington's disease, Parkinson's disease, postencephelatic Parkinsonism, progressive supranuclear palsy, Pick's disease, Niemann-Pick's disease, stroke, head trauma, bipolar disease, affective disorders, depression, schizophrenia, cognitive disorders and androgenetic alopecia. Thus, the dihydrochloride salt of oxindole II was prepd. in 68% yield by a coupling reaction of 5-cyanooxindole with 4-chloro-7-(2-morpholinoethoxy)quinazoline in DMF using NaH. The prepd. oxindoles were tested for GSK3 inhibition using the GSK3.beta. proximity assay.

MSTR 2



G1 = Ph (SO (1-2) G11)
G2 = alkyl<(1-3)>
MPL: claim 25

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 136:183610 MARPAT
TITLE: Heterocyclic sulfonamide derivatives
INVENTOR(S): Bender, David Michael; Forman, Scott Louis; Jones, Winton Dennis; Smith, Daryl Lynn; Zarrinmayeh, Hamideh; Zimmerman, Dennis Michael
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014294	A2	20020221	WO 2001-US21121	20010727
WO 2002014294	A3	20020606		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001082865	A5	20020225	AU 2001-82865	20010727
EP 1309577	A2	20030514	EP 2001-961615	20010727
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003225127	A1	20031204	US 2003-343186	20030401
PRIORITY APPLN. INFO.:			US 2000-224573P	20000811
			WO 2001-US21121	20010727

AB The present invention provides certain heterocyclic sulfonamide derivs. useful for potentiating glutamate receptor function in a patient and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurol. disorders. Fifteen title compds. such as 6-[4-(1-methyl-2-{[(methylethyl)sulfonyl]amino}ethyl)phenyl]-3-hydrobenzothiazol-2-one, and 5-[4-((1R)- and -(1S)-1-methyl-2-{[(methylethyl)sulfonyl]amino}ethyl)phenyl]indolin-2-ones were prepd. in 17-67% yields by std. methods.

MSTR 1



G3 = phenylene (SO (1-2) G5)
G4 = 62



G6 = alkyl<(1-6)>
G10 = O
G13 = 55



MPL: claim 1
NTE: substitution is restricted
NTE: or pharmaceutically acceptable salts

L5 ANSWER 3 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 136:183609 MARPAT
TITLE: Heterocyclic sulfonamide derivatives
INVENTOR(S): Forman, Scott Louis; Jones, Winton Dennis; Smith, Daryl Lynn; Zarrinmayeh, Hamideh; Zimmerman, Dennis Michael
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014275	A2	20020221	WO 2001-US21122	20010727
WO 2002014275	A3	20020530		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2001080470	A5	20020225	AU 2001-80470	20010727
EP 1313719	A2	20030528	EP 2001-958860	20010727
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003220369	A1	20031127	US 2003-332941	20030113
PRIORITY APPLN. INFO.:			US 2000-224497P	20000811
			WO 2001-US21122	20010727

AB The present invention provides certain heterocyclic sulfonamide derivs. useful for potentiating glutamate receptor function in a patient and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurol. disorders. Ten title compds. such as 4-, 5-, 6- and 7-[4-(1-fluoro-1-methyl-2-{[(methylethyl)sulfonyl]amino}ethyl)phenyl]indol-2-ones were prepd. in 20-50% yields by std. methods.

MSTR 1



G3 = phenylene (SO (1-2) G5)
G4 = 62



G6 = alkyl<(1-6)>
G10 = O
G13 = 55



MPL: claim 1
NTE: substitution is restricted
NTE: or pharmaceutically acceptable salts

L5 ANSWER 4 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 136:64132 MARPAT
TITLE: Use of microsomal triglyceride transfer protein inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles
INVENTOR(S): Grutzmann, Rudi; Muller, Ulrich; Bischoff, Hilmar; Zaiss, Siegfried

PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001097787	A2	20011227	WO 2001-EP6526	20010608
WO 2001097787	A3	20021114		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10030375	A1	20020103	DE 2000-10030375	20000621
EP 1296681	A2	20030402	EP 2001-951571	20010608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003535888	T2	20031202	JP 2002-503264	20010608
US 2004014748	A1	20040122	US 2003-311761	20030512
PRIORITY APPLN. INFO.:			DE 2000-10030375	20000621
			WO 2001-EP6526	20010608

AB Inhibitors of the microsomal triglyceride transfer protein are used for reducing the no. of postprandial triglyceride-rich lipoprotein particles or for reducing their decompn. products i.e. the cholesterol-rich "small remnant particle" (remnants). The particles are assocd. with apolipoprotein B-48.

MSTR 2



G1 = 45



G2 = Ph

G5 = C(O)
G6 = O
MPL: claim 4
NTE: and salts
STE: and isomeric forms

L5 ANSWER 5 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:180701 MARPAT
TITLE: Preparation of 4-hydroxyoxoindoles
INVENTOR(S): Furukawa, Yoshiro
PATENT ASSIGNEE(S): Daiso Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001226351	A2	20010821	JP 2000-34472	20000214

PRIORITY APPLN. INFO.: JP 2000-34472 20000214
OTHER SOURCE(S): CASREACT 135:180701
GI



I



II

AB Title compds. I (R1-R6 = H, alkyl, cycloalkyl, aryl, aralkyl, etc.) are prepd. by dehydrogenation of dioxoindoles II (R1-R6 = same as above) in solvents. 2,4-Dioxo-2,3,4,5,6,7-hexahydroindole was dehydrogenated in the presence of Pd/C in ethylene glycol monobutyl ether acetate under reflux to give 95% 2,3-dihydro-4-hydroxy-2-oxoindole.

MSTR 2



G1 = CO2H (SO) / Ph
MPL: claim 1

L5 ANSWER 6 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:76794 MARPAT
TITLE: High-yield method for producing 2-indolones by the reduction of isatins with hydrazine hydrate in the presence of tertiary amine catalysts
INVENTOR(S): Hendel, Wolfram; Schwendinger, Karl; Felfer, Ulfried
PATENT ASSIGNEE(S): DSM Fine Chemicals Austria G.m.b.H., Austria
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047884	A1	20010705	WO 2000-EP12010	20001130
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AT 9902182	A	20010215	AT 1999-2182	19991227
AT 408223	B	20010925		
EP 1242376	A1	20020925	EP 2000-988767	20001130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004014986	A1	20040122	US 2002-168848	20020626
PRIORITY APPLN. INFO.:			AT 1999-2182	19991227
			WO 2000-EP12010	20001130

OTHER SOURCE(S): CASREACT 135:76794
GI



I



II

AB 2-Indolones (I; R = H, CH3, Ph, PhCH2; R1 = H, C1-4 alkyl, alkoxy, Ph, phenoxy, halogen, amino, nitro, hydroxy) (e.g., 2-indolone) are prepd. in high yield and selectivity by redn. of the corresponding isatins (II; e.g., 2,3-indoledione) with hydrazine hydrate in a polar solvent (e.g., 2-ethylhexanol) at 15-185.degree. to form an unisolated corresponding isatin hydrazone which directly undergoes further redn. to form the corresponding 2-indolone by adding diazabicyclooctane and/or diazabicycloundecane and/or ethyldiisopropylamine as a catalyst at 100-185.degree. and then the produced reaction water is distd. off. The I is isolated from the reaction mixt. by distg. off the solvent and by means of crystn. in an ether solvent.

MSTR 1



G1 = Me
G2 = Ph
MPL: claim 1

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 134:193446 MARPAT
TITLE: Preparation of heterocyclic compounds as inhibitors of factor Xa
INVENTOR(S): Zhu, Bing-Yan; Scarborough, Robert M.; Clizbe, Lane; Doughan, Brandon; Jia, Zhaozhong-Jon; Kane-Maguire, Kim; Marlowe, Charles; Song, Yonghong; Su, Ting; Teng, Willy; Zhang, Penglie
PATENT ASSIGNEE(S): Cor Therapeutics, Inc., USA; et al.
SOURCE: PCT Int. Appl., 387 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012600	A1	20010222	WO 2000-US21742	20000810
WO 2001012600	C2	20020912		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6534535	B1	20030318	US 2000-636804	20000810
PRIORITY APPLN. INFO.:			US 1999-148627P	19990812
			US 2000-202202P	20000505

GI



I



II

AB The title compds. [I; A = alkyl, cycloalkyl, (un)substituted Ph, etc.; Q = a direct link, CH2, CO, etc.; D = (un)substituted Ph, 6-membered heteroaryl having 1-2 ring N atoms; M = NR16CO, NR16CS, CR17R18CO, etc.; R16-R18 = H, halo, alkyl, etc.; E = a direct link, CO, CONR5, etc.; R5 = alkyl, alkenyl, alkynyl, etc.; G = a direct link, CR7R8, CR7aR8aCR7bR8b, CR7c:CR8c; R7, R8, R7a, R7b, R7c, R8a, R8b, R8c = H, halo, alkyl, etc.; J = a direct link, O, S, etc.; Y = (un)substituted Ph, naphthyl, monocyclic or fused bicyclic heterocyclyl; L = H, CN, CONR12R13; R12, R13 = H, alkyl, OH, etc.] having activity against mammalian factor Xa, and useful in vitro or in vivo for preventing or treating coagulation disorders, were prepd. and formulated. E.g., a multi-step synthesis of the title compd. II was given.

MSTR 1



G1 = 27-28 25-2 26-3



G3 = 41-1 42-3



G4 = CH2 (SO)
G5 = O
G10 = Ph (SO)
G18 = 131-3 133-112



MPL: claim 1
NTE: additional ring formation also claimed
NTE: substitution is restricted

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 134:76382 MARPAT
TITLE: Combinations of microsomal triglyceride-exchanging protein (MTP) inhibitors and HMG CoA reductase inhibitors and their use in medicaments
INVENTOR(S): Gruetzmann, Rudi; Mueller, Ulrich; Bischoff, Hilmar
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 44 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

DE 19929065	A1	20001228	DE 1999-19929065 19990625
WO 2001000183	A2	20010104	WO 2000-EP5410 20000613
WO 2001000183	A3	20010510	

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1196194	A2	20020417	EP 2000-942056 20000613

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: DE 1999-19929065 19990625
WO 2000-EP5410 20000613

AB The invention concerns the use of a combination of at least one selected MTP inhibitor (component A) and an HMG CoA reductase inhibitor (component B) for the fight against cardiovascular illnesses. An example of component A is (2S)-2-cyclopentyl-2-[4-(2,4-dimethylpyrido[2,3-b]indol-9-ylmethyl)phenyl]-N-(2-(1R)hydroxy-1-phenylethyl)acetamide. An example of component B is Atorvastatin.

MSTR 2



G1 = 34



G2 = Ph
G6 = C(O)
G7 = O
MPL: claim 1

L5 ANSWER 9 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 134:76381 MARPAT
TITLE: Combinations of microsomal triglyceride-exchanging protein (MTP) inhibitors with hypolipemics and their use in medicaments
INVENTOR(S): Gruetzmann, Rudi; Mueller, Ulrich

PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 46 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19929031	A1	20001228	DE 1999-19929031	19990625
WO 2001000184	A2	20010104	WO 2000-EP5417	20000613
WO 2001000184	A3	20010705		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: DE 1999-19929031 19990625

AB The invention concerns the use of a combination of at least one MTP inhibitor (component A) as well as vitamins and substances affecting lipid metab. for the fight against cardiovascular diseases, (component B), and the prodn. and use of this combination. An example of an A component is (2S)-2-cyclopentyl-2-[4-(2,4-dimethylpyrido[2,3-b]indol-9-ylmethyl)phenyl]-N-(2-hydroxy-1-phenylethyl)acetamide. An example of a B component is Gemfibrozil.

MSTR 2



G1 = 34



G2 = Ph
G6 = C(O)
G7 = O
MPL: claim 1

L5 ANSWER 10 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 134:76380 MARPAT
TITLE: Combination of microsomal triglyceride-exchanging protein (MTP) inhibitors and metabolism-affecting active substances and its use in medicaments
INVENTOR(S): Gruetzmann, Rudi; Mueller, Ulrich
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 46 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19929012	A1	20001228	DE 1999-19929012	19990625
WO 2001000189	A2	20010104	WO 2000-EP5575	20000616
WO 2001000189	A3	20010802		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: DE 1999-19929012 19990625

AB The invention concerns the use of a combination of at least one selected MTP inhibitor (component A) and metab.-affecting active substances (component B) for the fight against illnesses; medicaments contg. this combination and its prodn. are disclosed. An example of component A is (2S)-2-cyclopentyl-2-[4-(2,4-dimethylpyrido[2,3-b]indol-9-ylmethyl)phenyl]-N-(2-(1R)hydroxy-1-phenylethyl)acetamide. Component B may include antidiabetic agents, antioxidants, cytostatics, calcium antagonists, antihypertensives, thyroid agents, anticoagulants, etc.

MSTR 2



G1 = 34



G2 = Ph
G6 = C(O)
G7 = O
MPL: claim 1

L5 ANSWER 11 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 133:217719 MARPAT
TITLE: 3-(Cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors, and their therapeutic use
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald; Blake, Robert A.
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: U.S., 61 pp., Cont. -in-part of U.S. Ser. No. 99,842.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6114371	A	20000905	US 1998-190970	19981112
US 6130238	A	20001010	US 1998-99842	19980619
US 2002183370	A1	20021205	US 2001-29946	20011231
US 6579897	B2	20030617		
PRIORITY APPLN. INFO.:			US 1997-50977P	19970620
			US 1997-59384P	19970919
			US 1998-99842	19980619
			US 1997-50413P	19970620
			US 1997-59544P	19970919
			US 1998-99721	19980619
			US 2000-482198	20000112

OTHER SOURCE(S): CASREACT 133:217719
AB 3-(Cyclohexano-heteroarylidenyl)-2-indolinone compds., and physiol. acceptable salts and prodrugs thereof, are disclosed which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase-related cellular disorders (cancer, arthritis, restenosis, etc.).

MSTR 2



G2 = O
G7 = CO2H (SO)
G12 = 146

p-C6H4OMe
146

MPL: claim 18

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 131:209113 MARPAT
TITLE: Antimycobacterial isatin and oxindole derivatives for the treatment of mycobacterial diseases
INVENTOR(S): Ramachandran, Janakiraman
PATENT ASSIGNEE(S): Astra AB, Swed.
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9944608	A1	19990910	WO 1999-SE319	19990304
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2320757	AA	19990910	CA 1999-2320757	19990304
AU 9927573	A1	19990920	AU 1999-27573	19990304
AU 735381	B2	20010705		
BR 9908510	A	20001121	BR 1999-8510	19990304
EP 1058548	A1	20001213	EP 1999-908059	19990304
EP 1058548	B1	20030917		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002505286	T2	20020219	JP 2000-534210	19990304
NZ 506217	A	20020531	NZ 1999-506217	19990304
AT 249828	E	20031015	AT 1999-908059	19990304
NO 2000004419	A	20001020	NO 2000-4419	20000905
PRIORITY APPLN. INFO.:			IN 1998-MA464	19980306
			SE 1998-1370	19980420
			WO 1999-SE319	19990304

AB The use of certain isatin and oxindole derivs. in the prepn. of a medicament for use in the treatment of mycobacterial diseases is disclosed. Thus, 1-nonyl-7-phenyl-1H-indol-2,3-dione was prepd. by the reaction of 1-bromononane with 7-phenyl-1H-indole-2,3-dione (I). The MIC of I against Mycobacterium tuberculosis was .ltoreq.20 .mu.g/mL.

MSTR 1



G1 = Ph
G2 = CH2
G4 = (3-7) CH2
DER: and pharmaceutically acceptable salts or solvates
MPL: claim 1

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 130:320831 MARPAT
TITLE: Application of 3-substituted aryl oxidized indole compounds
INVENTOR(S): Yang, Chunzheng; Xie, Ping; Duan, Jianrong; Miao, Hua; Song, Xianmei
PATENT ASSIGNEE(S): Hematology Inst., Chinese Academy of Medical Sciences, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 21 pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1115640	A	19960131	CN 1994-107957	19940726
CN 1051452	B	20000419		
PRIORITY APPLN. INFO.:			CN 1994-107957	19940726

GI



AB The title compds. used to prep. anti-tumor and/or anti-leukemia drug have a structure of (I) as follows: where, R1=H, halogen, alkyl, alkenyl, Ph, OH, alkoxy, or OC(O)R(R=alkyl), or C(O)R (R=H, CH3, Ar, NR'R''(R'R''=alkyl), or COOR (R=H, CH3, C1-3alkyl or M+), or NHR (R=H, alkyl or NO2); R2=H, CH3, Ar or NR'2 (R'=H or alkyl)). 3-Substituted aryl

oxidized indole compd. (R1,R2 is the same as compd. I) was reacted with triphenyl-2-nitrobenzylphosphonium bromide by Wittig's reaction, then reacted by Friedel-craft's reaction to give the title compds.

MSTR 2



G1 = Ph
G2 = Me
MPL: claim 3

L5 ANSWER 14 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 129:267876 MARPAT
TITLE: Negative charging electrophotographic toner containing benzoheterocyclic compound as charge-controlling agent
INVENTOR(S): Murai, Takayuki; Tanioka, Miya; Yoshioka, Takashi
PATENT ASSIGNEE(S): Shikoku Chemicals Corp., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10239910	A2	19980911	JP 1997-57076	19970224

PRIORITY APPLN. INFO.: JP 1997-57076 19970224
GI



I



II



III

AB The toner contains benzoheterocyclic compd. I (R1-5 = H, alkyl, aryl, halo, nitro, cyano, OH, alkoxy, carboxyl, alkoxycarbonyl, acyloxy, amino), II (R1 = H, alkyl, aryl; R2-3 = H, alkyl, aryl, halo, alkoxy), or III (R1 = H, alkyl, aryl; R2-3 = H, alkyl, aryl, halo, nitro, cyano, alkoxy, carbamoyl, carboxyl, alkoxycarbonyl) as a charge-controlling agent. The compd. shows good charging-controlling ability and the toner gives clear white or pale-color images without toner scattering.

MSTR 3



G1 = Me
G2 = Ph
MPL: claims

L5 ANSWER 15 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 129:76520 MARPAT
TITLE: Vitronectin-receptor antagonists
INVENTOR(S): Wehner, Volkmar; Stilz, Hans-ulrich; Peyman, Anuschirwan; Scheunemann, Karlheinz; Ruxer, Jean-Marie; Carniato, Denis; Lefrancois, Jean-Michel; Gadek, Thomas Richard; McDowell, Robert
PATENT ASSIGNEE(S): Hoechst A.-G., Germany; Genentech Inc.
SOURCE: Ger. Offen., 52 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent

LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19653645	A1	19980625	DE 1996-19653645	19961220
EP 854145	A2	19980722	EP 1997-121931	19971212
EP 854145	A3	20000322		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
ZA 9711315	A	19980622	ZA 1997-11315	19971217
BR 9706386	A	20030422	BR 1997-6386	19971217
AU 9748464	A1	19980625	AU 1997-48464	19971218
AU 729760	B2	20010208		
CA 2225267	AA	19980620	CA 1997-2225267	19971219
NO 9705975	A	19980622	NO 1997-5975	19971219
CN 1200373	A	19981202	CN 1997-129789	19971219
JP 10182617	A2	19980707	JP 1997-365528	19971222
US 5990145	A	19991123	US 1997-995522	19971222
US 2001011087	A1	20010802	US 2001-778755	20010208
US 6482821	B2	20021119		
US 2003119785	A1	20030626	US 2002-299001	20021119
PRIORITY APPLN. INFO.:			DE 1996-19653645	19961220
			US 1997-995522	19971222
			US 1999-412314	19991005
			US 2001-778755	20010208

AB Compds. contg. a nitrogen heterocycle and a fibrinogen receptor antagonist are claimed for use as vitronectin receptor antagonists and to inhibit bone resorption (no data).

MSTR 1



G12 = 522-9 526-29



G14 = alkylene<(1-)> (SO)
G25 = phenylene
DER: and physiologically acceptable salts
MPL: claim 1
NTE: substitution is restricted

L5 ANSWER 16 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 128:128032 MARPAT
TITLE: Preparation of heterocyclyl-substituted phenoxyalkanoic acids as fibrinogen receptor antagonists
INVENTOR(S): Duggan, Mark E.; Egbertson, Melissa S.; Hartman, George D.; Young, Steven D.; Ihle, Nathan C.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 270 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9800134	A1	19980108	WO 1997-US11133	19970625
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2258093	AA	19980108	CA 1997-2258093	19970625
AU 9735798	A1	19980121	AU 1997-35798	19970625
AU 721130	B2	20000622		
EP 912175	A1	19990506	EP 1997-932307	19970625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2000514061	T2	20001024	JP 1998-504291	19970625
PRIORITY APPLN. INFO.:			US 1996-20975P	19960628
			GB 1997-893	19970117
			WO 1997-US11133	19970625

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. X-Y-Z-A-B [I; X = (un)substituted 5-7- membered arom. or nonarom. ring, having 1-3 heteroatoms selected from N, O, and S, (un)substituted 9-10 membered fused arom. or nonarom. ring, having 1-3 heteroatoms selected from N, O, and S; Y = (un)substituted 5-6 membered arom. or nonarom. ring, having 0-3 heteroatoms selected from N, O, and S; XY = II, III, IV, V; Z = C(O)NR4, N(R4)C(O), CH2CH2, CH:CH, etc.; R4 = H, C1-4 alkyl, C3-6 cycloalkyl; A = (un)substituted 5-6 membered arom. ring, having 0-3 heteroatoms selected from N, O, and S, 9-10 membered fused arom. ring having 0-3 heteroatoms (N, O, and S); B = C(CH2)mCO2R9, (CH2)nCO2R9, CH(R8)(CH2)pCO2R9, OCH(R8)(CH2)pCO2R9 (wherein m = 1-3; n = 0-3; p = 0-3; R8 = H, aryl, amino, etc.; R9 = H, aryl, C1-8 alkyl, etc.)], useful in inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus or embolus formation, inhibiting osteoclast mediated bone resorption, inhibiting angiogenesis, and in inhibiting tumor growth, were prepd. and formulated. Thus, a few-step detailed synthesis of the acid VI which showed IC50 in the range between 10 nM and 50 mM against ADP-stimulated platelet aggregation, was described.

MSTR 1B



G9 = phenylene (SO)
G18 = 307-19 311-5



DER: and pharmaceutically acceptable salts
MPL: claim 1

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 127:108938 MARPAT
TITLE: Preparation of benzoheterocyclylmethylphenylacetamides as antiatherosclerotics.
INVENTOR(S): Connell, Richard; Goldmann, Siegfried; Mueller, Ulrich; Lohmer, Stefan; Bischoff, Hilmar; Denzer, Dirk; Gruetzmann, Rudi; Wohlfeil, Stefan
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Eur. Pat. Appl., 57 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 779279	A1	19970618	EP 1996-119321	19961203
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
DE 19546918	A1	19970619	DE 1995-19546918	19951215
US 5811429	A	19980922	US 1996-761921	19961209
JP 09183766	A2	19970715	JP 1996-352429	19961213
US 6025378	A	20000215	US 1998-99557	19980618
US 6200971	B1	20010313	US 1999-420304	19991018

PRIORITY APPLN. INFO.: DE 1995-19546918 19951215
US 1996-761921 19961209
US 1998-99557 19980618

GI



I

AB Title compds. [I; A = (substituted) benzimidazolyl, oxoquinazolinyl, oxophthalazinyl, etc.; R1 = alkyl, cycloalkyl, (substituted) Ph; R2 = H, alkyl; R3 = H, alkyl, cycloalkyl, (substituted) Ph, heterocyclyl; R4 = H, CH2OH, CH2O2CR11; R11 = H, alkyl, (substituted) Ph; D, E = H, halo, CF3, OH, CO2H, alkyl, alkoxy, alkoxycarbonyl; Z = O, S], were prepd. Thus, 2-cyclopentyl-2-[4-(2-methyl-4-oxo-4H-quinazolin-3-ylmethyl)phenyl]acetic acid (prepn. given) was stirred overnight with (R)-phenylglycinol, hydroxybenzotriazole, N'-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride, and Et3N in CH2Cl2 to give 51% 2-cyclopentyl-N-(2-hydroxy-1-phenylethyl)-2-[4-(2-methyl-4-oxo-4H-quinazolin-3-ylmethyl)phenyl]acetic acid amide (II). II inhibited liberation of ApoB-100 assocd. lipoproteins with IC50 = 44.4 nM.

MSTR 1



G1 = 38



G2 = Ph
G3 = C(O)
G4 = O
DER: and salts
MPL: claim 1
NTE: substitution is restricted

L5 ANSWER 18 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 126:293359 MARPAT
TITLE: Preparation of (S)-3-aralkylamino-2-hydroxypropoxybenzoazoles and analogs as .beta.3-adrenoceptor agonists
INVENTOR(S): Jesudason, Cynthia Darshini; Matthews, Donald Paul; Mcdonald, John Hampton; Neel, David Andrew; Rito, Christopher John; Shuker, Anthony John; Bell, Michael Gregory; Crowell, Thomas Alan; Droste, Christine Ann; Winter, Mark Alan
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: Eur. Pat. Appl., 62 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 764640	A1	19970326	EP 1996-306851	19960920
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
ZA 9607892	A	19980318	ZA 1996-7892	19960918
IL 134420	A1	20010913	IL 1996-134420	19960919
CA 2232434	AA	19970327	CA 1996-2232434	19960920
WO 9710825	A1	19970327	WO 1996-US15135	19960920
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9670778	A1	19970409	AU 1996-70778	19960920
AU 715175	B2	20000120		
CN 1202107	A	19981216	CN 1996-198236	19960920
BR 9610852	A	19990713	BR 1996-10852	19960920
JP 11512701	T2	19991102	JP 1996-512930	19960920
US 5939443	A	19990817	US 1997-882503	19970625
US 6060492	A	20000509	US 1997-882587	19970625
US 5977154	A	19991102	US 1997-882931	19970626
NO 9801203	A	19980506	NO 1998-1203	19980317
US 6093735	A	20000725	US 1999-345976	19990701
US 6265581	B1	20010724	US 2000-551184	20000417
PRIORITY APPLN. INFO.:			US 1995-4082P	19950921
			US 1996-708621	19960905
			IL 1996-119270	19960919
			WO 1996-US15135	19960920
			US 1997-850562	19970502
			US 1997-882931	19970626

GI



II

AB (S)-R1Z1CH(OH)CH2NR3CR5R6Z2R4 [I; R1 = heterocyclo-fused Ph group, e.g., II;R3 = H, alkyl, aryl; R4 = R9-substituted Ph, -naphthyl, -cycloalkyl, etc.; R5,R6 = H or alkyl; R7R8 = (un)substituted NA3A4 or (un)substituted NA3:A4; A3,A4 = C or N (sic); R9 = halo, alkyl, alkoxy, aryloxy, etc.; Z1 = bond, OCH2, SCH2; Z2 = bond or alkylene] were prepd. Thus, 4-(HO)C6H4CH2OH was condensed with Me2CHNO2 and the reduced product etherified by 6-chloronicotinamide to give 6-[4-(2-amino-2-methylpropyl)phenoxy]nicotinamide which was condensed with (S)-4-glycidyloxyindole to give I [R1 = 4-indolyl, R3 = H, R4 = C6H4[OC6H4(CONH2)-4]-4, R5 = R6 = Me, Z1 = OCH2, Z2 = CH2]. Data for biol. activity of I were given.

MSTR 1



G1 = 108-2 105-99



G7 = O
G8 = 41 / CH2



G9 = Ph (SO)
G10 = Me
DER: or pharmaceutically acceptable salts
MPL: claim 1
NTE: substitution is restricted

L5 ANSWER 19 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 125:142587 MARPAT
TITLE: Process for preparation of (alkenyl)benzazepinones
INVENTOR(S): Berger, Joel G.; Chang, Wei K.; Kozlowski, Joseph A.; Zhou, Guowei
PATENT ASSIGNEE(S): Schering Corp., USA
SOURCE: U.S., 13 pp., Cont.-in-part of U.S. 5,241,065. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5530125	A	19960625	US 1994-290894	19940819
US 5241065	A	19930831	US 1992-841603	19920225
WO 9316997	A1	19930902	WO 1993-US1425	19930223

W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG

PRIORITY APPLN. INFO.: US 1992-841603 19920225
WO 1993-US1425 19930223

GI



I



II

AB A process for the prepn. of .alpha.-substituted arylethylamines I (R, R1 = substituent; R4 = alkenyl, cycloalkenyl; p = 0-3) comprises the treatment of an arylacetamide with a strong base in an inert aprotic org. solvent, followed by reaction with a zerovalent transition metal catalyst and then with a compd. of the formula R X, (R4 = 1-alkenyl, 1-cycloalkenyl; X = leaving group). The .alpha.-substituted arylacetamides are useful as intermediates in the prepn. (by redn.) of .alpha.-substituted arylethylamines, e.g., 1-substituted-2,3,4,5-tetrahydro-1H-3-benzazepines, having pharmacol. activity. Certain benzazepines wherein the 1-substituent R4 = 1-(1-cycloalkenyl) are new. For example, the alkenylation of 7-chloro-1,3,4,5-tetrahydro-8-methoxy-3-methyl-2H-3-benzazepin-2-one with cyclohexenyl triflate in the presence of tetrakis(triphenylphosphine)palladium gave 7-chloro-1-(1-cyclohexen-1-yl)-1,3,4,5-tetrahydro-8-methoxy-3-methyl-2H-3-benzazepin-2-one (II).

MSTR 2



G2 = alkyl<(1-10)> (SO cycloalkyl<(3-8)>)
G10 = Ph (SO (1-) G3)
MPL: claim 5

L5 ANSWER 20 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 125:33651 MARPAT
TITLE: Preparation of [(tetrahydropyridoindolyl)alkyl]benzazolinone derivatives having serotonin 5-HT1D.alpha. receptor activity
INVENTOR(S): Gilmore, Jeremy; Gallagher, Peter Thaddeus; Miles, Martin Victor; Owton, William Martin; Smith, Colin William
PATENT ASSIGNEE(S): Lilly Industries Ltd., UK
SOURCE: Can. Pat. Appl., 34 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2157998	AA	19960313	CA 1995-2157998	19950911
US 5563147	A	19961008	US 1995-462237	19950605
EP 705832	A1	19960410	EP 1995-306253	19950907
EP 705832	B1	20030813		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 247114	E	20030815	AT 1995-306253	19950907
AU 9530497	A1	19960328	AU 1995-30497	19950908
AU 698580	B2	19981105		
HU 72593	A2	19960528	HU 1995-2631	19950908
HU 219491	B	20010428		
CZ 286565	B6	20000517	CZ 1995-2322	19950908
FI 9504243	A	19960313	FI 1995-4243	19950911
NO 9503575	A	19960313	NO 1995-3575	19950911
JP 08081464	A2	19960326	JP 1995-231873	19950911
ZA 9507607	A	19960517	ZA 1995-7607	19950911
CN 1129219	A	19960821	CN 1995-117133	19950911
CN 1045602	B	19991013		
IN 179550	A	19971018	IN 1995-CA1079	19950911
IL 115236	A1	19980615	IL 1995-115236	19950911
RU 2146256	C1	20000310	RU 1995-115522	19950911
PRIORITY APPLN. INFO.:			GB 1994-18326	19940912
			GB 1995-11166	19950602

GI



I



II



AB Pharmaceutical compds. of the formula [I; R1, R7 = halo, CF3, C1-6 alkyl,

C1-6 alkoxy, each optionally substituted Ph, naphthyl, or heteroaryl; R2, R3 = H or C1-6 alkyl; R4, R5 = H, halo, CF3, C1-6 alkyl, C1-6 alkoxy, each optionally substituted Ph, naphthyl, or heteroaryl; R6 = H, C1-6 alkyl, each optionally substituted Ph, naphthyl, heteroaryl, or phenyl-C1-6 alkyl, CO2R8 (where R8 is an ester group); m, p = 0-4; n =1-4; Z = NR9, O, S, CR9R10; R9, R10 = H, C1-6 alkyl, optionally substituted phenyl-C1-6 alkyl; X = O, S; Y = Q, Q1 (where R11, R12 = H, C1-6 alkyl, CF3, each optionally substituted Ph, naphthyl, or heteroaryl)] and salts and solvates thereof, which are useful for the treatment of diseases of central nervous system such as obesity, bulimia, alcoholism, pain, depression, hypertension, aging, memory loss, sexual dysfunction, anxiety, schizophrenia, gastrointestinal disorders, headache, cardiovascular disorders, smoking cessation, drug addiction, and emesis, are prepd. Thus, 8.7 mmol 1-[2-(1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol-2-yl)-1-ethyl]-1,3-dihydrobenzimidazol-2-one was suspended in 50 mL Me iso-Bu ketone, treated with 9.58 mmol 1-(2-chloroethyl)-1,3-dihydro-2H-benzimidazol-2-one, 10.45 mmol Na2CO3, and 10 mg Bu4NI, and the suspension was heated to 90.degree. for 2 days to give the title compd. (II). A total of 23 I were prepd. and showed binding affinity to 5-HT1D.alpha. receptor with Ki values 20-5,000 nM and also possessed binding activity at the 5-HT1D.beta. and 5-HT2A receptors.

MSTR 1



G1 = Ph (SO)
G3 = (1-4) 51



G7 = 65



G9 = O
DER: and salts and solvates
MPL: claim 1

L5 ANSWER 21 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 125:10614 MARPAT

TITLE: Preparation of benzannelated five-membered heterocyclecarboxamides as 5-HT receptor antagonists
INVENTOR(S): Forbes, Ian Thomson; Jones, Graham Elgin; King, Francis David; Ham, Peter; Davies, David Thomas; Moghe, Angela
PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9602537	A1	19960201	WO 1995-EP2637	19950706
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 770076	A1	19970502	EP 1995-943540	19950706
R: BE, CH, DE, FR, GB, IT, LI, NL				
JP 10502653	T2	19980310	JP 1995-504647	19950706
US 5922733	A	19990713	US 1997-765933	19970630
PRIORITY APPLN. INFO.:			GB 1994-14139	19940713
			WO 1995-EP2637	19950706

GI



I



II

AB Title compds. [I; R3 = halo, NH2, OH, alkyl, etc.; Z1 = XYZCONR2Z2R1 or X:YZCONR2Z2R1 (Z = CH or N), XY:ZCONR2Z2R1 (Z = C); R1 = H, halo, alkyl, alkoxy, etc.; R2 = H or alkyl; X,Y = O, S, CO, CH, CH2, NH, etc; Z2 = phenylene, (iso)quinolinediyl, heterocyclylene; n = 0-3] were prepd. as 5-HT2B and 5-HT2C receptor antagonists. Thus, 4,3-Br(MeO)C6H3SH was etherified by BrCH2COCO2Et and the product cyclized to give, after sapon., 5-bromo-6-methoxybenzo[b]thiophene-3-carboxylic acid which was amidated by 3-aminopyridine to give title compd. II. Selected I had Ki.gtoreq.7.2 for binding to rat or human 5-HT2C clones expressed in 293 cell in vitro.

MSTR 1

G1---G4---C(O)G6

G6 = 70



G7 = N
G8 = C(O) / CH2
G13 = Ph (SO)
DER: and pharmaceutically acceptable salts
MPL: claim 1
NTE: substitution is restricted
NTE: additional ring formation specified

L5 ANSWER 22 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 123:83356 MARPAT
TITLE: Preparation of 3-(1-piperazinyl)-1,2-benzisothiazole derivatives with antipsychotic effect
INVENTOR(S): Fukuda, Yoshimasa; Sasaki, Toshiro; Nakatani, Yuuko; Ichimaru, Yasuyuki; Imanishi, Taiichiro
PATENT ASSIGNEE(S): Meiji Seika K. K., Japan
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9418197	A1	19940818	WO 1994-JP159	19940203
W: CN, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 635506	A1	19950125	EP 1994-905841	19940203
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
CN 1103534	A	19950607	CN 1994-190042	19940203
CN 1050604	B	20000322		
US 5599815	A	19970204	US 1994-318857	19941220
PRIORITY APPLN. INFO.:			JP 1993-17505	19930204
			WO 1994-JP1	19940104
			WO 1994-JP159	19940203

GI



I



AB Compds. represented by general formula [I; n = 2-4; W = heterocyclyl, e.g., Q - Q2; m = 0-2; A = CH2, CH, N, NH; B = CH2, CH, N, NH, S; provided that both A and B .noteq. N or NH; X = CH, N, S, bond; Y = CH, N; R1 = H, halo, lower (halo)alkyl, (un)substituted Ph, OH, NO2, lower alkoxy, NH2, cyano; R2, R3 = H, halo, lower (halo)alkyl or alkoxy, NH2, cyano, provided that when X = bond, R2 is not present; or R2R3 = (CH2)p (wherein p = 3-5)] and pharmacol. acceptable salts thereof, reduced in the adverse effect against the extrapyramidal system and hence useful as an antipsychotic agent with few side effects, are prepd. Thus, 0.29 g 2-hydroxyquinoline was dissolved in DMF and treated with 80 mg NaH at 60.degree. for 30 min with stirring followed by cooling the reaction mixt. to room temp. and adding 2.16 g 1,4-dibromobutane and the resulting mixt. was stirred at 60.degree. for 4 h to give 64% 1-(4-bromobutyl)-2(1H)-quinolinone (II). II 0.56, 3-(1-piperazinyl)-1,2-benzisothiazole 0.44, and K2CO3 0.33 g were suspended in DMF and stirred at room temp. for 12 h to give 80% title compd. I (n = 4, W = 2-oxo-1,2-dihydro-1-quinolinyl). II (n = 4, W = 9-carbazolyl) and II (n = 3, W = 2-oxo-1,2-dihydro-1-quinolinyl) showed ED50 of 1.15 and 0.92 mg/kg i.p., resp., for inhibiting methamphetamine-induced spontaneous movement of mice (vs. 0.16 and 1.05 mg/kg i.p. for haloperidol and chlorpromazine, resp.) and induced catalepsy in mice at ED50 of >100 and 83.3 mg/kg i.p. in mice (vs. 1.3 and 6.2 mg/kg i.p. for haloperidol and chlorpromazine, resp.).

MSTR 1



G1 = (2-4) CH2
G2 = 77



G17 = Ph (SO (1-) G5)
G18 = 184



DER: and pharmacologically acceptable salts
MPL: claim 1

L5 ANSWER 23 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 122:239719 MARPAT
TITLE: 1-substituted isatin and oxindole derivatives as inhibitors of acetylcholinesterase
INVENTOR(S): Boar, Bernard Robin; Oshea, Dennis Mark; Tomlinson, Ian David
PATENT ASSIGNEE(S): Astra AB, Swed.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9429272	A1	19941222	WO 1994-SE448	19940513
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2164119	AA	19941222	CA 1994-2164119	19940513
AU 9470108	A1	19950103	AU 1994-70108	19940513
EP 703901	A1	19960403	EP 1994-919032	19940513
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08511515	T2	19961203	JP 1994-501642	19940513
NO 9505074	A	19960207	NO 1995-5074	19951214
FI 9506074	A	19951218	FI 1995-6074	19951218
PRIORITY APPLN. INFO.:			SE 1993-2080	19930616
			WO 1994-SE448	19940513

GI



I

AB The title compds. [I; W = hydrogen, lower alkyl, lower alkoxy, halogen; X = hydrogen, lower alkyl, aryl, lower alkoxy, halogen, trifluoromethyl, nitro, NHCOR, (un)substituted NH2; R = lower alkyl, aryl; Y = CO, (un)substituted CH2; Z = lower alkyl; n = 3-7] [e.g., 5'-(1-piperidinyl)-spiro-[1,3-dioxolane-2,3'-[3H]-indol]-2'(1'H)-one], useful as acetylcholinesterase inhibitors (no data) for the treatment of cognitive dysfunction (no data), Alzheimer's disease (no data), Down's syndrome (no data), Parkinson's disease (no data), glaucoma (no data), etc. (no data), are prepd. and I-contg. formulations presented.

MSTR 1



G1 = Ph (SO (1-) G2)
G4 = 18

G6 = (3-7) CH2
DER: and pharmaceutically acceptable salts and solvates
MPL: claim 1
STE: and stereo and optical isomers and racemates

L5 ANSWER 24 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 122:81401 MARPAT
TITLE: Preparation of piperazinylisoxazole derivatives as antipsychotics with low extrapyramidal side effects
INVENTOR(S): Fukuda, Yoshimasa; Yamazaki, Naoki; Sasaki, Toshiro; Imanishi, Taiichiro; Hiranuma, Toyoichi
PATENT ASSIGNEE(S): Meiji Seika Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 18 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06234753	A2	19940823	JP 1993-22910	19930210
PRIORITY APPLN. INFO.:			JP 1993-22910	19930210

GI



I



II

AB The title compds. I [R1 - R3 = H, halo, Q1, etc.; n = 0 - 5; one of R1 - R3 is Q1; R4 = Q2, etc.; m = 0 - 5] are prepd. Piperazinylisoxazole deriv. cis-II (prepn. given) showed ED50 of 1.2 mg/Kg i. p. against methamphetamine-induced hyperactivity in mice, vs. ED50 of 1.1 mg/Kg i.p. for chlorpromazine (III). In a test for catalepsy-inducing effect in mice, cis-II showed ED50 of >100 mg/Kg i.p., vs. ED50 of 6.2 mg/Kg i.p. for III.

MSTR 1



G3 = (0-5) CH2
G4 = 103



G9 = Ph
DER: or pharmacologically acceptable salts
MPL: claim 1

L5 ANSWER 25 OF 35 MARPAT COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 121:133948 MARPAT
TITLE: Process for the preparation of methylated or hydroxyethylated 5-membered heterocycles
INVENTOR(S): Fischer, Rolf; Pinkos, Rolf
PATENT ASSIGNEE(S): BASF A.-G., Germany
SOURCE: Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 602515	A1	19940622	EP 1993-119734	19931208
EP 602515	B1	19980715		
R: BE, CH, DE, FR, GB, LI, NL				
DE 4242451	A1	19940623	DE 1992-4242451	19921216
US 5453516	A	19950926	US 1993-165463	19931213

PRIORITY APPLN. INFO.: DE 1992-4242451 19921216
GI



AB The title compds. (I; R1 = Me, hydroxyethyl; R2-R6 = H, C1-12 alkyl, C2-12 alkenyl, aryl, halogen, etc.; X = O, NR4) are readily prepd. by reacting heterocycle II (Y = H, acetyl, C2-20 alkoxycarbonyl) with di-Me carbonate or ethylene carbonate in the presence of a N-contg. base at 50-300.degree./0.01-50 bar. Thus, 4-methylbutyrolactone, di-Me carbonate, and NMe3 where reacted at 200.degree. in an autoclave for 5 h, producing 2,4-dimethylbutyrolactone (b.p. 70-74.degree./10 mbar) in 74% yield.

MSTR 1B



G2 = alkyl<(1-18)> (SR alkoxycarbonyl<(1-18)>) / Ph
G9 = 238



MPL: claim 1

L5 ANSWER 26 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 119:225964 MARPAT
TITLE: Isatin derivative cholinesterase inhibitors and processes for their preparation
INVENTOR(S): Boar, Bernard Robin; Cross, Alan John
PATENT ASSIGNEE(S): Aktiebolaget Astra, Swed.
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9312085	A1	19930624	WO 1992-SE873	19921216
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, RO, RU, SD, SE, UA				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
ZA 9209700	A	19930810	ZA 1992-9700	19921214
AU 9331759	A1	19930719	AU 1993-31759	19921216
AU 675055	B2	19970123		
EP 624156	A1	19941117	EP 1993-900490	19921216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07502272	T2	19950309	JP 1992-510848	19921216
HU 69704	A2	19950928	HU 1994-1844	19921216
SK 278321	B6	19961002	SK 1994-734	19921216
PL 170736	B1	19970131	PL 1992-304124	19921216
CN 1079464	A	19931215	CN 1992-115358	19921218
CN 1034939	B	19970521		
NO 9402316	A	19940617	NO 1994-2316	19940617
FI 9402913	A	19940817	FI 1994-2913	19940617
US 5585378	A	19961217	US 1995-467695	19950606
PRIORITY APPLN. INFO.:			SE 1991-3752	19911218
			WO 1992-SE873	19921216
			US 1992-992407	19921217
			US 1995-417724	19950406

GI



I



II



III

AB The title compds. I [G = (un)substituted Ph, (un)substituted cyclohexyl; X

= H, alkyl, aryl, aryloxy, CN, alkoxy, halogen, hydroxy, NO2, CF3, alkylsulfonamido, etc.; Y = CO, R4CR3; R3, R4 = H, alkyl, alkoxy; Z = N, CH; n = 1-3; q = 1, 2; R3R4 = cyclic acetal], useful as cholinesterase inhibitors in the treatment of cognitive dysfunction, are prepd. by the condensation haloalkyl-substituted heterocyclic deriv. II (E = halogen) with indole deriv. III or by the corresponding condensation of haloalkyl-substituted indole derivs. with phenylalkyl-substituted piperazine derivs. Thus, 5-methyl-1H-indole-2,3-dione was condensed with 1-(2-chloroethyl)-4-(phenylmethyl)piperazine, and the condensate treated with ethanolic HCl, producing 5-methyl-1-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-1H-indole-2,3-dione dihydrochloride (m.p. 270-275.degree., decompn.).

MSTR 1



G3 = Ph (SO (1-) G4)
G7 = 28



DER: and pharmaceutically acceptable acid addition salts and solvates
MPL: claim 1
NTE: substitution is restricted
STE: and isomers and racemates

L5 ANSWER 27 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 118:11497 MARPAT
TITLE: Hair dye comprising isatin or derivatives thereof associated with a tri-, tetra- or pentasubstituted aniline or a bisphenylalkylenediamine
INVENTOR(S): Lang, Gerard; Cotteret, Jean
PATENT ASSIGNEE(S): Oreal S. A., Fr.
SOURCE: Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 502784	A1	19920909	EP 1992-400558	19920304
EP 502784	B1	19950621		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, PT, SE

FR 2673533	A1	19920911	FR 1991-2615	19910305
FR 2673533	B1	19930611		
CA 2062280	AA	19920906	CA 1992-2062280	19920304
US 5261926	A	19931116	US 1992-845586	19920304
ES 2073876	T3	19950816	ES 1992-400558	19920304
JP 04360818	A2	19921214	JP 1992-48491	19920305
JP 3330625	B2	20020930		
PRIORITY APPLN. INFO.:			FR 1991-2615	19910305

GI



I

AB Hair dyes comprise isatin or isatin derivs. (Markush given) and a bisphenylalkylenediamine or an aniline deriv. I [Y = OH, (un)substituted NH2; R - R3 = H, alkyl, Cl, acetylamino, alkoxy, aryloxy]. A compn. (pH 8; triethanolamine) comprised isatin 1, 2,6-dimethyl-1,4-diaminobenzene 1, EtOH 30 and water to 100 g.

MSTR 1



G1 = COMe
G2 = Ph (SO alkyl<(1-6)>)
MPL: claim 1

L5 ANSWER 28 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 117:257972 MARPAT
TITLE: Hair dye comprising isatin or derivatives thereof associated with an aminopyridine derivative
INVENTOR(S): Lang, Gerard; Cotteret, Jean
PATENT ASSIGNEE(S): Oreal S. A., Fr.
SOURCE: Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 502783	A1	19920909	EP 1992-400557	19920304

EP 502783	B1	19950503			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, PT, SE					
FR 2673532	A1	19920911	FR 1991-2614	19910305	
FR 2673532	B1	19930611			
US 5279616	A	19940118	US 1992-845587	19920304	
AT 121930	E	19950515	AT 1992-400557	19920304	
ES 2072108	T3	19950701	ES 1992-400557	19920304	
CA 2062359	AA	19920906	CA 1992-2062359	19920305	
JP 04368318	A2	19921221	JP 1992-48492	19920305	
JP 3330626	B2	20020930			
US 5340366	A	19940823	US 1993-136125	19931015	
PRIORITY APPLN. INFO.:			FR 1991-2614	19910305	
			US 1992-845587	19920304	

GI



AB Isatin or an isatin deriv. (Markush given), assocd. with a dimethylpyridine deriv. I (R = H, 2-HOCH2CH2; m = 0, 1; n = m, 2) or a pyrimidine deriv. II [R1 = (un)substituted NH2; R2 = H, OH, R1; R3 = H, NH2; R4 = OH, R1] is a hair dye. A compn. (pH 7.6; triethanolamine) comprised isatin 1, tetraaminopyrimidine 1, EtOH 30, and water to 100 g.

MSTR 1



G1 = COMe
G2 = Ph (SO alkyl<(1-6)>)
MPL: claim 1

L5 ANSWER 29 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 117:233851 MARPAT
TITLE: Preparation of hydrazonoindolones as excitatory amino acid antagonists
INVENTOR(S): Dahl, Bjarne Hugo; Waetjen, Frank
PATENT ASSIGNEE(S): Neurosearch A/S, Den.
SOURCE: Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

EP 503349	A1	19920916	EP 1992-103104	19920224
EP 503349	B1	19950104		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
US 5164404	A	19921117	US 1991-670061	19910315
ZA 9201328	A	19921125	ZA 1992-1328	19920224
ES 2069330	T3	19950501	ES 1992-103104	19920224
AU 9211225	A1	19920917	AU 1992-11225	19920226
AU 643877	B2	19931125		
CA 2062853	AA	19920916	CA 1992-2062853	19920312
NO 9201000	A	19920916	NO 1992-1000	19920313
NO 180191	B	19961125		
NO 180191	C	19970305		
JP 05078350	A2	19930330	JP 1992-55531	19920313
JP 3407896	B2	20030519		
PRIORITY APPLN. INFO.:			US 1991-670061	19910315

GI



I

AB Title compds. I [n = 0, 1; R1 = H, C1-6 alkyl, C3-7 cycloalkyl, CH2Ph, (substituted) Ph, acyl, OH, C1-6 alkoxy, CH2CO2H, CH2CN, etc.; R2 = (substituted) Ph, -pyridyl; R4 - R7 = H, C1-36 alkyl, Ph, halo, C1-6 alkoxy, NO2, cyano, CF3, SO2NR11R12; R11, R12 = H, CH2Ph, C1-6 alkyl; or R6R7 or R4R5 = atoms to complete a 4-8 membered (substituted) carbocyclic ring] were prepd. for the treatment of disorders responsive to the blockade of glutamic or aspartic receptors. Thus, 5-nitro-1H-6,7,8,9-ttrahydrobenz[g]indole-2,3-dione (prepn. given) and 2-nitrophenylhydrazone were stirred in MeOH contg. HCl to give 5-nitro-1H-6,7,8,9-tetrahydrobenz[g]indole-2,3-dione-3-(2-nitrophenylhydrazone) as a mixt. of E- and Z-isomers. I are said to exhibit binding at 3H-kainate, NMDA, 3H-AMPA and/or 3H-glycine binding sites with IC50's of 1-100 .mu.M.

MSTR 2A



G2 = CH2Ph (SO)
G8 = Ph
MPL: claim 10

L5 ANSWER 30 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 117:178123 MARPAT
TITLE: hair dye preparation containing isatine and an aminoindole or an aminoindoline derivative.
INVENTOR(S): Lang, Gerard; Cotteret, Jean
PATENT ASSIGNEE(S): Oreal S. A., Fr.
SOURCE: Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 497697	A1	19920805	EP 1992-400237	19920130
EP 497697	B1	19951206		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, PT, SE				
FR 2672210	A1	19920807	FR 1991-1186	19910201
FR 2672210	B1	19930521		
US 5190564	A	19930302	US 1992-828299	19920130
AT 131035	E	19951215	AT 1992-400237	19920130
ES 2089431	T3	19961001	ES 1992-400237	19920130
CA 2060488	AA	19920802	CA 1992-2060488	19920131
JP 04338321	A2	19921125	JP 1992-16805	19920131

PRIORITY APPLN. INFO.: FR 1991-1186 19910201
AB A hair dye compn. contained isatine 1, 6-aminoindole 1, EtOH 30 (pH 8.1), and water 100 by wt. The compn. gave a copper color to the 90% gray hair.

MSTR 1



G1 = COMe
G2 = Ph (SO alkyl<(1-6)>)
DER: and cosmetically acceptable salts
MPL: claim 1

L5 ANSWER 31 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 116:255341 MARPAT
TITLE: Preparation of N-substituted tetrahydronaphthyl-N-hydroxyureas and analogs as 5-lipoxygenase inhibitors
INVENTOR(S): Adams, Jerry Leroy; Garigipati, Ravi Shanker; Griswold, Don Edgar; Schmidt, Stanley James
PATENT ASSIGNEE(S): SmithKline Beecham Corp., USA
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9114674	A2	19911003	WO 1991-US2010	19910325
WO 9114674	A3	19920109		
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2078126	AA	19910928	CA 1991-2078126	19910325
AU 9175875	A1	19911021	AU 1991-75875	19910325
AU 660277	B2	19950622		
EP 522000	A1	19930113	EP 1991-907085	19910325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05505610	T2	19930819	JP 1991-506661	19910325
ZA 9102264	A	19920429	ZA 1991-2264	19910326
PRIORITY APPLN. INFO.:			US 1990-500153	19900327
			US 1990-500179	19900327
			WO 1991-US2010	19910325

GI



I



II

AB Title compds. I (R1 = H, C1-10 alkyl, C1-10 alkoxy, etc.; R2, R3 = R4C:BN(ORa), R4 = (halo)(hydroxy) C1-6 alkyl, C2-6 alkenyl, (halo)heteroaryl, C1-6 alkoxy, R5R6N wherein R5 = H, alkyl, R6 = C1-6 alkyl, aryl, PhCH2, etc.; B = O, S, Ra = H, cation, aroyl, C1-12 alkoyl; W = CH2(CH2)s, O(CH2)s, S(CH2)s, NR7(CH2)s, s = 0-3, R7 = H, C1-4 alkyl, Ph, C1-6 alkoyl, aroyl; l = q = 0, 1) or a salt thereof, are prepd. I are also analgesics. To 6-hydroxy-1-tetralone was added NaH, followed by 4-(MeO)C6H4CH2Cl and the mixt. was heated to 90.degree. for 1 h to give the tetralone derivs. To this in pyridine was added HONH2.HCl to give the oxime, which was treated with BH3-pyridine and converted to the N-hydroxyamine deriv. to which was added Me3SiNCO to give after work up the title compd. II. II inhibited 5-lipoxygenase with IC50 of 0.5 .mu.M and an analgesic activity ED50 of 10 mg/kg.

MSTR 3H



G1 = O
G12 = 23



G14 = CHO
G15 = Ph (SO)
MPL: claim 30

L5 ANSWER 32 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 115:183089 MARPAT
TITLE: Preparation of isatin derivatives as central nervous system (CNS) agents
INVENTOR(S): Watjen, Frank; Drejer, Jorgen; Jensen, Leif Helth
PATENT ASSIGNEE(S): Neurosearch A/S, Den.
SOURCE: Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 432648	A2	19910619	EP 1990-123474	19901206
EP 432648	A3	19910925		
EP 432648	B1	19950802		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ZA 9009479	A	19910925	ZA 1990-9479	19901126
JP 03204856	A2	19910906	JP 1990-330898	19901130
JP 3057095	B2	20000626		
FI 9005943	A	19910612	FI 1990-5943	19901203
ES 2077623	T3	19951201	ES 1990-123474	19901206
CA 2031756	AA	19910612	CA 1990-2031756	19901207
CA 2031756	C	20020611		
NO 9005320	A	19910612	NO 1990-5320	19901210
NO 174464	B	19940131		
NO 174464	C	19940511		
AU 9067920	A1	19910613	AU 1990-67920	19901210
AU 629075	B2	19920924		
US 5198461	A	19930330	US 1991-710790	19910605
PRIORITY APPLN. INFO.:			DK 1989-6248	19891211
			DK 1989-6470	19891219
			DK 1990-85	19900112
			DK 1990-86	19900112
			DK 1990-363	19900212
			DK 1990-2093	19900831
			US 1990-624409	19901207

GI



AB Isatin derivs. [I; R1 = H, linear or branched C1-6 alkyl, C3-7 cycloalkyl,

(substituted) Ph, PhCH2, OH, acyl, etc.; R2 = H, PhCH2, linear or branched C1-6 alkyl, C3-7 cycloalkyl; R4-R7 = H, linear or branched C1-6 alkyl, C1-6 alkoxy, Ph, halo, NO2, cyano, etc.], esp. useful in treating CNS conditions sensitive to excitatory amino acids. To a stirred soln. of diketone II (R1 = H, Z = O) in DMF was added 55% NaH in mineral oil, followed by MeI with stirring at room temp. to give II (R1 = Me, Z = O), which was treated with MeONH2.HCl and Na2CO3 at room temp. to give oxime II (R1 = Me, Z = MeON). Also prepd. were 54 addnl. I which were effective in treating CNS disorders at 30-100 mg/day.

MSTR 2



G1 = CH2Ph
G7 = Ph
MPL: claim 13

L5 ANSWER 33 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 114:42571 MARPAT
TITLE: Preparation of intermediates for making 2-oxindole-1-carboxamides
INVENTOR(S): Kelly, Sarah E.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4952703	A	19900828	US 1989-357138	19890525
EP 399748	A2	19901128	EP 1990-305464	19900521
EP 399748	A3	19920108		
EP 399748	B1	19960124		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 133409	E	19960215	AT 1990-305464	19900521
ES 2083427	T3	19960416	ES 1990-305464	19900521
CA 2017328	AA	19901125	CA 1990-2017328	19900523
JP 03011061	A2	19910118	JP 1990-135177	19900524
JP 07119211	B4	19951220		
US 5086186	A	19920204	US 1990-531952	19900531
JP 07215935	A2	19950815	JP 1994-293236	19941128
JP 2500853	B2	19960529		

PRIORITY APPLN. INFO.: US 1989-357138 19890525
OTHER SOURCE(S): CASREACT 114:42571
GI



I

AB The title intermediates, i.e. N-(trichloroacetyl) amides I [X = H, Br, Cl, F, C1-4 alkyl, C3-7 cycloalkyl, C1-4 alkoxy, C1-4 alkylthio, F3C, etc.; Y = H, Br, Cl, F, C1-4 alkyl, C3-7 cycloalkyl, C1-4 alkoxy, C1-4 alkylthio, F3C; or XY = methylenedioxy, ethylenedioxy, XYC = trimethylene, tetramethylene, etc.; R = H, R1CO, R1 = C1-6 alkyl, (substituted) Ph, naphthyl, etc.], are prepd. and hydrolyzed to 2-oxindole-1-carboxamides useful as analgesics and antiinflammatories or intermediates thereof. 5-Chloro-2-oxindole, MePh and Cl3CCONCO were warmed to 80.degree. to give I (X = R = H; Y = 5-Cl) (II). II, MeOH and H2SO4 were heated to 45.degree. to give 2-chloro-2-oxindole-1-carboxamide.

MSTR 1A



G1 = Ph
G4 = 10-1 11-4 8-3 / 10-1 12-4 8-3 / 10-1 13-4 8-3 /
11-1 10-4 8-3 / 11-1 12-4 8-3 / 11-1 13-4 8-3 /
12-1 10-4 8-3 / 12-1 11-4 8-3 / 12-1 13-4 8-3 /
13-1 10-4 8-3 / 13-1 11-4 8-3 / 13-1 12-4 8-3



MPL: claim 1

L5 ANSWER 34 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 113:217781 MARPAT
TITLE: Preparation of 3-aryliminoindolin-2-one hair dyes
INVENTOR(S): Anderson, James S.; Schultz, Thomas M.
PATENT ASSIGNEE(S): Bristol-Myers Co., USA
SOURCE: Eur. Pat. Appl., 9 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 359465	A2	19900321	EP 1989-309007	19890906
EP 359465	A3	19901227		
EP 359465	B1	19931118		
R: BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
US 4921503	A	19900501	US 1988-243525	19880912
CA 1327938	A1	19940322	CA 1988-583086	19881115
JP 02104778	A2	19900417	JP 1989-234827	19890912
JP 2929203	B2	19990803		
PRIORITY APPLN. INFO.:			US 1988-243525	19880912

GI



I

AB The title compds. I [R1 = H, alkyl, Ac, Bz, Ph; R2, R3 = H, alkyl, OH, NH2, halo, NO2, etc.; R4, R5 = H, halo, alkyl, (un)substituted Ph, etc.] are hair dyes. I may be prepd. in situ from the corresponding isatins and anilines. A soln. of 1 g isatin and 1 g p-phenylenediamine in 30 mL EtOH and 70 mL H2O was applied to hair for 20 min, to produce a red color. I (11) were prepd. as usual.

MSTR 1



G1 = COMe
G2 = Ph (SO (1-) alkyl<(1-6)>)
MPL: claim 1

L5 ANSWER 35 OF 35 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 111:153842 MARPAT
TITLE: Neuroleptic arylpiperazinylalkyl-substituted heterocycles and their pharmaceutical compositions and use
INVENTOR(S): Lowe, John A., III.; Nagel, Arthur A.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 9 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4831031	A	19890516	US 1988-146886	19880122
IN 173938	A	19940813	IN 1988-DE139	19880219
US 4883795	A	19891128	US 1989-300995	19890123

PRIORITY APPLN. INFO.: US 1988-146886 19880122
OTHER SOURCE(S): CASREACT 111:153842
GI



I



II

AB Title compds. I [Ar = benzothiazolyl, benzothiadiazolyl, benzotriazolyl, benzoxazolyl, benzoxazolonyl, indolyl, phthalazinyl, (un)substituted naphthyl, quinolyl, isoquinolyl, benzoisothiazolyl indanyl, 3-indazolyl; n = 1, 2; X and Y plus attached Ph = benzimidazolonyl, benzotriazolyl, (un)substituted quinolyl, benzothiazolyl, benzoisothiazolyl, indazolyl, indolyl, spiro[cyclopentaneindolinyl]] are prepd. as neuroleptics (no data). Benzoxazolone was acylated by BrCH2CO2H and polyphosphoric acid, and the bromoacetyl deriv. reduced by Et3SiH and CF3CO2H, to give 11% 6-(2-bromoethyl)benzoxazolone. Alkylation of N-(3-benzisothiazolyl)piperazine by the bromide in MIBK contg. Na2CO3 gave benzoxazolone II.

MSTR 1B



G4 = 75



G5 = alkyl<(1-3)> / 213 / 210 / 215



G7 = 213 / 210 / 215



DER: or a pharmaceutically acceptable acid addition salt
MPL: claim 1

=> d his

(FILE 'HOME' ENTERED AT 15:37:16 ON 25 FEB 2004)

FILE 'REGISTRY' ENTERED AT 15:37:20 ON 25 FEB 2004
L1 STRUCTURE UPLOADED
L2 1 S L1 SAM
L3 11 S L1 FULL

FILE 'CA' ENTERED AT 15:37:45 ON 25 FEB 2004
L4 1 S L3

FILE 'MARPAT' ENTERED AT 15:37:59 ON 25 FEB 2004
L5 35 S L1 FULL

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 15:40:14 ON 25 FEB 2004